- Collegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER
- Collegium to Report First Quarter 2024 Financial Results on May 9, 2024
- Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026
- Collegium to Participate in 23rd Annual Needham Virtual Healthcare Conference
- Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results
- Collegium to Report Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
- Collegium Provides 2024 Financial Guidance
- Appeals Court Upholds PTAB’s Finding of Invalidity of Purdue’s 961 Patent
- Collegium Announces $25 Million Accelerated Share Repurchase Program
- Collegium to Participate in Upcoming Investor Conferences
More ▼
Key statistics
On Wednesday, Collegium Pharmaceutical Inc (COLL:NSQ) closed at 37.78, -7.74% below its 52-week high of 40.95, set on Mar 28, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 37.12 |
---|---|
High | 38.47 |
Low | 37.03 |
Bid | 36.82 |
Offer | 39.71 |
Previous close | 36.93 |
Average volume | 338.98k |
---|---|
Shares outstanding | 32.71m |
Free float | 32.25m |
P/E (TTM) | 41.86 |
Market cap | 1.21bn USD |
EPS (TTM) | 0.8823 USD |
Data delayed at least 15 minutes, as of May 01 2024 21:15 BST.
More ▼